Buy Cadila Healthcare; target Rs 854: KRChoksey

7131 Investors following Cadila Health. Share this News with them.

0

Like this story, share it with millions of investors on M3

Buy Cadila Healthcare; target Rs 854: KRChoksey

KRChoksey is bullish on Cadila Healthcare (CHL) and has recommended buy rating on the stock with a target of Rs 854 in its February 9, 2012 research report.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sell Adani Power; target of Rs 57: Emkay Accumulate ICRA: PPFAS Research Accumulate ILandFS Trans; target of Rs 235: Angel Broking ALSO READ See previous views by KRChoksey See what other Experts & Brokerages are saying about Cadila Health See messages about Cadila Health Cadila Health BSE | NSE 01/06/12 Are Mutual Funds betting on Cadila Health?

KRChoksey is bullish on Cadila Healthcare (CHL) and has recommended buy rating on the stock with a target of Rs 854 in its February 9, 2012 research report.

"Cadila Healthcare (CHL) reported a yearly growth of 18.6% & 12% q-o-q mainly on the back of acquisitions done in the past months. Biochem, Bremer & Nesher drives the Topline growth. However EBITDA only grew marginally at 2.1% y-o-y & degrew by - 5.2% q-o-q & stood at Rs 262cr. Operating profit margins stood at 18.9%, a decline of 304bps y-o-y & 339bps q-o-q. Decline of the margins was mainly on the back of contribution from low margin segments. Reported PAT including forex losses stood at Rs 149cr and adjusted PAT stood at Rs 177cr, in line with our expectations. Net profit margins remained under pressure at 12.8%, a decline of 114bps y-o-y & 276bps q-oq. The lower margins were mainly due to higher depreciation expense partially offset by lower tax expense. Also the interest payment was bit higher both on a sequential & y-o-y basis. Overall the company reported muted performance for the quarter & is consolidating its past acquisitions which would pay off in the coming quarters."

"The company reported top-line of Rs 1383cr, a growth of 18.6% y-o-y & 11.9% q-o-q. Indian market including Biochem reported a growth of 11.2% y-o-y. The growth was mainly on the back of 15 new product launches including the line extensions. US market registered a growth of ~45% including Nesher. The total ANDA filings as on today stands at 141. Also the growth has been driven by rupee depreciation. CDL's consumer business has registered negative growth of ~12% mainly due to increased competition in the skincare segment. The company has taken aggressive steps to arrest the degrowth & is confident of crossing Rs 500mark till FY13. JV's performance was better on a sequential basis but pressure still exists as Hospira has not launched any products & competition has increased in the existing products."

"Weak EBITDA numbers were a result of higher contribution from low margin segment as well as higher R&D expenses. EBITDA for Q3FY12 stood at Rs 262cr & degrew by ~5.2% q-o-q. Operating margins stood at 18.9% which declined by 304bps & 339bps y-o-y & q-o-q respectively. R&D expense stood at ~6% to the total sales no & is expected to be in the same range in the coming quarters. PAT adjusted for forex losses of Rs 32cr for Q3FY12 stood at Rs 177cr, a meager growth of 8.9% y-o-y. Net profit margins stood at 12.8%, it's lowest in the last 8 quarters mainly due to higher depreciation & interest expense."

"We believe that the company should bottom out in the coming quarter and superior performance could be expected from FY13 onwards. All the past acquisitions should aid in terms of growth. However, we have reduced our earnings estimate mainly on the back of higher expenses in the coming years along with CDL establishing its presence in the low margins segment. We value the company at 20x its FY13 EPS of Rs 42.7 & recommend BUY with a target price of Rs 854, an upside of 27.8% to the current levels," says KRChoksey research report.

Shares held by Central Governments/State Governments

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment